1. Scrip
  2. >>Business

Could COVID-19 Variants Upend Global Vaccine Supply Deals?

WHO Approval Softens South Africa Blow For AZ Partner

 
• By Vibha Ravi

South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?

Return policy. online store orders, company policies and good service concept. Text under torn paper
How Would Inventory Returns Work In COVID-19 Vaccine Supply Deals? • Source: Shutterstock

In a world struggling for sufficient supplies of COVID-19 vaccines, South Africa refused to use one million doses of AstraZeneca PLC/University of Oxford partner Serum Institute of India Pvt. Ltd.’s vaccine, instead donating the lot to the African Union (AU). Another 500,000 doses are due to arrive in South Africa over the next few weeks and their fate is not yet clear.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.